Clinical Trials Browser

Active not recruiting × Lutetium × 90 days × Clear all

NCT06379217 2026-06-10

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Phase 1 Active not recruiting

EndocrineGenitourinary

Metastatic Neuroendocrine Prostate Cancer

NCT05849298 2026-05-27

PSMACare

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT06894511 2026-05-01

PSMAndARPI

Phase 2 Active not recruiting

Metastatic Castration Resistant Prostate Cancer (mCRPC)